International Epidemiology of Carbapenemase-Producing Escherichia coli
Authors:
- 8 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (4) , 499-509
Abstract
Carbapenemase-producing (CP) Escherichia coli (CP-Ec) are a global public health threat. We aimed to describe the clinical and molecular epidemiology and outcomes of patients from several countries with CP-Ec isolates obtained from a prospective cohort. Patients with CP-Ec were enrolled from 26 hospitals in 6 countries. Clinical data were collected and isolates underwent whole genome sequencing. Clinical and molecular features and outcomes associated with isolates with or without metallo-β-lactamases (MBL) were compared. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture. Of the 114 CP-Ec isolates in CRACKLE-2, 49 harbored an MBL, most commonly blaNDM-5 (38/49, 78%). Strong regional variations were noted with MBL-Ec predominantly found among patients in China (23/49). Clinically, MBL-Ec were more often from urine source (49% vs. 29%), less often met criteria for infection (39% vs 58%, p=0.04), and had lower acuity of illness when compared to non-MBL-Ec. Among patients with infection, the probability of a better DOOR outcome for a randomly selected patient with MBL-Ec as compared to non-MBL-Ec was 62% [95% CI: 48.2, 74.3]. Among infected patients, non-MBL-Ec had increased 30-day (26% vs 0%; p=0.02) and 90-day (39% vs 0%, p=0.001) mortality compared with MBL-Ec. Emergence of CP-Ec was observed with important geographic variations. Bacterial characteristics, clinical presentations, and outcomes differed between MBL-Ec and non-MBL-Ec. Mortality was higher among non-MBL isolates, which were more frequently isolated from blood, but these findings may be confounded by regional variations.Keywords
Funding Information
- NIAID
- NIH (UM1AI104681)
- US National Institute of Child Health and Human Development (1T32HD094671)
This publication has 30 references indexed in Scilit:
- Global dissemination of extensively drug‐resistant carbapenemase‐producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection controlJournal of Internal Medicine, 2015
- Global Incidence of Carbapenemase-Producing Escherichia coli ST131Emerging Infectious Diseases, 2014
- RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogeniesBioinformatics, 2014
- Predictive scoring model of mortality in Gram-negative bloodstream infectionClinical Microbiology and Infection, 2013
- Dissemination of the KPC-2 carbapenemase in non-Klebsiella pneumoniae enterobacterial isolates from ColombiaInternational Journal of Antimicrobial Agents, 2013
- Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patientsCleveland Clinic Journal of Medicine, 2013
- High Frequency of IMP-6 among Clinical Isolates of Metallo-β-Lactamase-Producing Escherichia coli in JapanAntimicrobial Agents and Chemotherapy, 2012
- Features of Infections Due to Klebsiella pneumoniae Carbapenemase–Producing Escherichia coli: Emergence of Sequence Type 131Clinical Infectious Diseases, 2012
- Resistance in gram-negative bacteria: EnterobacteriaceaeAmerican Journal of Infection Control, 2006
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987